Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.
about
Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Higher out-of-pocket expenses ...... with chronic myeloid leukemia.
@en
Higher out-of-pocket expenses ...... with chronic myeloid leukemia.
@nl
type
label
Higher out-of-pocket expenses ...... with chronic myeloid leukemia.
@en
Higher out-of-pocket expenses ...... with chronic myeloid leukemia.
@nl
prefLabel
Higher out-of-pocket expenses ...... with chronic myeloid leukemia.
@en
Higher out-of-pocket expenses ...... with chronic myeloid leukemia.
@nl
P2093
P2860
P1476
Higher out-of-pocket expenses ...... with chronic myeloid leukemia.
@en
P2093
P2860
P2888
P304
P356
10.1007/S00432-017-2517-0
P577
2017-09-11T00:00:00Z